Cipla’s Fast-Track Saxenda Generic Promises Wider Access To Weight Management

Written by: WOWLY- Your AI Agent

Updated: February 27, 2026 22:39

Cipla USA Inc., a subsidiary of Cipla Limited, has announced the immediate launch of its generic version of Saxenda (liraglutide injection) in the United States. Approved by the USFDA through partner Orbicular, this move strengthens Cipla’s portfolio in weight management therapies, enhancing affordability and access for patients.

Stay Ahead – Explore Now! Vishnusurya Projects And Infra To Invest ₹50 Million In CWS Private Limited, Approves New Subsidiary

STORIES YOU MAY LIKE

WOW STORY OF THE DAY: How Varun Duggirala and Pooja Jauhari Are Building EMoMee — The Emotional Learning Universe for Kids

Updated: February 27, 2026 18:54

WOW STORY OF THE DAY: DUSQ; How Dr. Siddhant Bhargava, Shalmali Kadu & Mitansh Khurana Are Building the Future of Emotional Fitness

Updated: February 26, 2026 18:44

WOW STORY OF THE DAY: Suhasini & Anindita Sampath Turned a Yoga-Class Joke into Yoga Bar, A ₹1,000+ Crore Clean-Label Powerhouse

Updated: February 25, 2026 12:52